This is a new T cell-mediated antitumor therapy in which cytotoxic T cells can be activated independently of major histocompatibility complex (MHC), thus eliminating dependence on the traditional T cell receptor-MHC pathway, can be severely compromised in the “cold” tumor microenvironment of prostate cancer (79). This evidence concerns the gene HLA-C and neoplasm.